Merit Medical Systems (NASDAQ:MMSI) Issues FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.250-4.350 for the period, compared to the consensus earnings per share estimate of 3.980. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI traded up $2.51 during mid-day trading on Thursday, hitting $83.35. The company had a trading volume of 2,024,596 shares, compared to its average volume of 691,109. Merit Medical Systems has a 12 month low of $59.74 and a 12 month high of $94.75. The firm has a market cap of $4.97 billion, a P/E ratio of 36.08, a PEG ratio of 2.51 and a beta of 0.52. The business’s 50-day simple moving average is $69.45 and its 200-day simple moving average is $71.69. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The firm had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same period in the previous year, the company posted $1.01 earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, analysts predict that Merit Medical Systems will post 3.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Wells Fargo & Company lowered their price target on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Needham & Company LLC dropped their price objective on shares of Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Barrington Research reduced their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Finally, Robert W. Baird set a $83.00 target price on shares of Merit Medical Systems in a research report on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $92.80.

Insiders Place Their Bets

In other news, insider Brian G. Lloyd bought 2,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were bought at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the purchase, the insider owned 2,000 shares of the company’s stock, valued at approximately $125,240. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lynne N. Ward sold 5,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director owned 7,809 shares in the company, valued at $488,921.49. This represents a 39.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in shares of Merit Medical Systems by 7.3% during the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock worth $1,730,000 after buying an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock worth $76,039,000 after acquiring an additional 103,878 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Merit Medical Systems by 745.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock worth $86,000 after acquiring an additional 813 shares during the last quarter. First Trust Advisors LP grew its position in Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock worth $5,535,000 after acquiring an additional 11,770 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after purchasing an additional 251 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.